CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 485 enrolled
Drug / intervention
MP0420 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05780463
NCT05780463Phase 3Completed
CompareCT.gov

A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 (Trial H5: MP0420)

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Mar 22, 2023·Updated Feb 5, 2024

In Brief

A Phase 3 clinical trial evaluating MP0420, Placebo, and 1 other intervention for COVID-19. Completed, enrolled 485 participants across 105 sites in 10 countries.

Detailed Summary

This study looks at the safety and effectiveness of MP0420 in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either MP0420 plus current standard of care (SOC), or with placebo plus current SOC. This is ACTIV-3/TICO Treatment Trial H5.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesDenmark, Greece, Nigeria, Poland, Singapore, Spain, Switzerland, Uganda, United Kingdom, United States
CollaboratorsInternational Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Medical Research Council, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Heart, Lung, and Blood Institute (NHLBI), US Department of Veterans Affairs, Prevention and Early Treatment of Acute Lung Injury, Cardiothoracic Surgical Trials Network, Molecular Partners AG, University of Minnesota

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMar 22, 2023
Enrollment StartJun 11, 2021
Primary CompletionFeb 23, 2022
Study CompletionJun 8, 2023
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 3.3 years ago

Interventions

MP0420drug

MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains.

Placebodrug

Commercially available 0.9% sodium chloride solution

Remdesivirbiological

Antiviral agent